Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1/2 1Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Multiple Myeloma 7Leukemia, Myeloid, Acute 4Myelodysplastic Syndromes 3Hodgkin Disease 3Breast Neoplasms 3Lymphoma 2Waldenstrom Macroglobulinemia 1Triple Negative Breast Neoplasms 1Sezary Syndrome 1Recurrence 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Neoplasm Metastasis 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Immunoblastic Lymphadenopathy 1

Interventions

ruxolitinib 9Peripheral Blood Stem Cell Transplantation 6Azacitidine 5Methotrexate 4Busulfan 4fludarabine phosphate 3Cyclosporine 3Whole-Body Irradiation 2Tacrolimus 2Mycophenolic Acid 2Cytarabine 2Antilymphocyte Serum 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2venetoclax 1vatalanib 1tagraxofusp 1sonidegib 1rucaparib 1pomalidomide 1pevonedistat 1pelcitoclax 1lestaurtinib 1givinostat hydrochloride 1givinostat 1fedratinib 1ethanolamine oleate 1axatilimab 1abiraterone 1Vitamin E 1Trimethoprim, Sulfamethoxazole Drug Combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Primary Myelofibrosis × Panobinostat × Clear all
NCT01298934 2015-03-06

LBH589 (Panobinostat) for the Treatment of Myelofibrosis

Icahn School of Medicine at Mount Sinai

Phase 1/2 Unknown
22 enrolled
Myeloid

Polycythemia Vera, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡